Oculis (NASDAQ:OCS) Price Target Raised to $40.00 at Needham & Company LLC

Oculis (NASDAQ:OCS) had its price objective raised by Needham & Company LLC from $36.00 to $40.00 in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a buy rating on the stock.

Other equities analysts also recently issued reports about the stock. Wall Street Zen raised shares of Oculis from a “sell” rating to a “hold” rating in a report on Saturday, November 15th. HC Wainwright lifted their target price on shares of Oculis from $36.00 to $42.00 and gave the company a “buy” rating in a research note on Tuesday, November 11th. JPMorgan Chase & Co. initiated coverage on Oculis in a report on Friday, December 19th. They issued an “overweight” rating and a $38.00 target price on the stock. Bank of America dropped their price target on Oculis from $30.00 to $29.00 and set a “buy” rating for the company in a report on Thursday, November 13th. Finally, Lifesci Capital assumed coverage on Oculis in a research report on Wednesday, December 3rd. They issued an “outperform” rating and a $55.00 price objective for the company. Eight equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $43.50.

Oculis Stock Performance

Shares of NASDAQ:OCS opened at $27.72 on Wednesday. The company has a debt-to-equity ratio of 0.02, a current ratio of 4.47 and a quick ratio of 4.47. The business’s fifty day moving average price is $25.89 and its two-hundred day moving average price is $21.44. Oculis has a fifty-two week low of $14.00 and a fifty-two week high of $30.68. The stock has a market capitalization of $1.45 billion, a price-to-earnings ratio of -12.21 and a beta of 0.29.

Oculis (NASDAQ:OCS) last issued its quarterly earnings data on Tuesday, March 3rd. The company reported ($0.51) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.08). Oculis had a negative net margin of 8,173.41% and a negative return on equity of 67.89%. The company had revenue of $0.50 million for the quarter, compared to the consensus estimate of $0.14 million. As a group, analysts predict that Oculis will post -2.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of OCS. Bank of America Corp DE increased its stake in shares of Oculis by 2.2% in the 2nd quarter. Bank of America Corp DE now owns 40,512 shares of the company’s stock valued at $786,000 after buying an additional 878 shares during the period. China Universal Asset Management Co. Ltd. boosted its holdings in Oculis by 100.0% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 2,000 shares of the company’s stock valued at $40,000 after acquiring an additional 1,000 shares during the last quarter. Aventura Private Wealth LLC acquired a new stake in Oculis in the fourth quarter worth about $80,000. Geode Capital Management LLC raised its holdings in Oculis by 27.7% during the 2nd quarter. Geode Capital Management LLC now owns 29,436 shares of the company’s stock worth $571,000 after purchasing an additional 6,384 shares during the last quarter. Finally, Compagnie Lombard Odier SCmA lifted its position in Oculis by 10.6% during the 4th quarter. Compagnie Lombard Odier SCmA now owns 107,300 shares of the company’s stock valued at $2,143,000 after purchasing an additional 10,300 shares during the period. Institutional investors and hedge funds own 22.30% of the company’s stock.

Oculis News Roundup

Here are the key news stories impacting Oculis this week:

• Positive Sentiment: Analysts raised price targets — HC Wainwright bumped its target to $44 (buy) and Needham raised its target to $40 (buy), giving the stock material upside vs. the current level; these upgrades can attract buying interest. Ticker Report
• Positive Sentiment: Company reported strong strategic progress in the Q4/2025 release: upcoming DIAMOND Phase 3 topline readout for OCS-01 in DME (Q2 2026), Breakthrough Therapy designation for Privosegtor advancing a large neuro-ophthalmology opportunity, and a clear R&D roadmap — these are meaningful clinical catalysts. Press Release
• Positive Sentiment: Balance sheet strength: Oculis reported $268.7M in cash and short-term investments at year-end 2025, which management says funds operations into 2029 — this reduces near-term financing risk and supports value for clinical milestones. Press Release
• Positive Sentiment: Oculis filed its 2025 financials and renewed a $100M at-the-market (ATM) equity program, giving the company optionality to raise capital opportunistically without immediate dilution — investors often view ATMs as a liquidity tool. TipRanks
• Neutral Sentiment: Company published notifications that RSUs vested and were settled for a director; this is routine insider compensation but can incrementally increase share count depending on settlement method. GlobeNewswire
• Negative Sentiment: Q4 earnings: Oculis reported a loss of $0.51/share, missing consensus (-$0.43) despite revenue topping estimates; EPS misses can pressure sentiment, especially for biotech names where near-term commercialization and cash burn matter. Earnings PDF

Oculis Company Profile

Oculis SA (NASDAQ: OCS) is a clinical-stage biopharmaceutical company focused on developing novel ophthalmic therapies designed primarily to treat retinal and neuro-ophthalmic diseases. Leveraging its proprietary technology platforms, Oculis aims to deliver therapeutic agents to the back of the eye through topical or nasal administration, potentially offering an alternative to current intravitreal injections. The company’s pipeline includes OCS-01, a topical dexamethasone formulation targeting diabetic macular edema; OCS-05, a neuroprotective candidate for acute optic neuritis and idiopathic intracranial hypertension; and OC-02, a nasal spray formulation of varenicline for dry eye disease.

Founded in 2016 and headquartered in Basel, Switzerland, Oculis operates research and development facilities across Europe and in the United States, with a presence in Cambridge, Massachusetts.